Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition
- PMID: 11705631
- DOI: 10.1016/s0197-4580(01)00245-7
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition
Abstract
Vaccinations with Abeta1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Abeta1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Abeta deposition, one group of mice with modest Abeta deposition, and one group with significant Abeta deposition. The effects of immunization on Abeta deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Abeta1-42 immunization was highly effective. Biochemically extracted Abeta40 and Abeta42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Abeta deposits selectively reduced Abeta42 without altering Abeta40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Abeta loads, Abeta1-42 immunization only minimally decreased Abeta42 levels, whereas no alteration in Abeta40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Abeta1-42 immunization is more effective at preventing additional Abeta accumulation and does not result in significant clearance of pre-existing Abeta deposits.
Similar articles
-
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.J Neurosci. 2003 Sep 17;23(24):8532-8. doi: 10.1523/JNEUROSCI.23-24-08532.2003. J Neurosci. 2003. PMID: 13679422 Free PMC article.
-
Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.Curr Alzheimer Res. 2017;14(6):656-667. doi: 10.2174/1567205013666161201201227. Curr Alzheimer Res. 2017. PMID: 27915995
-
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.J Clin Invest. 2006 Jan;116(1):193-201. doi: 10.1172/JCI25410. Epub 2005 Dec 8. J Clin Invest. 2006. PMID: 16341263 Free PMC article.
-
Novel Abeta immunogens: is shorter better?Curr Alzheimer Res. 2007 Sep;4(4):427-36. doi: 10.2174/156720507781788800. Curr Alzheimer Res. 2007. PMID: 17908047 Review.
-
A safer vaccine for Alzheimer's disease?Neurobiol Aging. 2002 Nov-Dec;23(6):1001-8. doi: 10.1016/s0197-4580(02)00124-0. Neurobiol Aging. 2002. PMID: 12470795 Review.
Cited by
-
Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.Neurochem Res. 2003 Jul;28(7):1017-27. doi: 10.1023/a:1023203122036. Neurochem Res. 2003. PMID: 12737526 Review.
-
T-cells in Alzheimer's disease.Neuromolecular Med. 2005;7(3):255-64. doi: 10.1385/NMM:7:3:255. Neuromolecular Med. 2005. PMID: 16247185 Review.
-
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.J Neurosci. 2007 Nov 14;27(46):12721-31. doi: 10.1523/JNEUROSCI.3201-07.2007. J Neurosci. 2007. PMID: 18003852 Free PMC article.
-
BRI2 (ITM2b) inhibits Abeta deposition in vivo.J Neurosci. 2008 Jun 4;28(23):6030-6. doi: 10.1523/JNEUROSCI.0891-08.2008. J Neurosci. 2008. PMID: 18524908 Free PMC article.
-
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.BMC Med. 2012 Oct 25;10:127. doi: 10.1186/1741-7015-10-127. BMC Med. 2012. PMID: 23098093 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical